Report top-line data from the Phase 3 SIENDO study in endometrial cancer
Delivered after the deadline (39 days after the deadline)
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 11 Feb 2021
- Due
- 31 Dec 2021
- Delivered
- 8 Feb 2022
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“top-line data from the Phase 3 SIENDO study in endometrial cancer expected in the second half of 2021.”
What we found
Evidence strength A What the grades mean
Top-line SIENDO data were announced on February 8, 2022, after the second-half 2021 deadline; in January 2022 the company had already guided to first quarter 2022.
-
A Karyopharm Therapeutics Inc. 10-K filed 2022-03-01
“On February 8, 2022, we announced top-line results from our Phase 3 SIENDO study evaluating the efficacy and safety of selinexor for front-line maintenance therapy in patients with advanced or recurrent endometrial cancer” ✓ confirmed on the page
-
A Karyopharm Therapeutics Inc. 8-K filed 2022-01-10
“Report top-line data from Phase 3 SIENDO study evaluating selinexor as a maintenance therapy in endometrial cancer in 1Q 2022.” ✓ confirmed on the page
-
A Karyopharm Therapeutics Inc. 8-K filed 2022-01-10
“Company on Track to Announce Top-Line Phase 3 Data from SIENDO Study Evaluating XPOVIO® (selinexor) in Patients with Endometrial Cancer in First Quarter 2022” ✓ confirmed on the page
Checked 26 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout late
- Indicative materiality
- High rules
- Action
- Report
- Deliverable
- Top-line data from Phase 3 SIENDO study
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Karyopharm Therapeutics Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-KPTI-023598 · Corrections policy